Tier 2 — strong

Effects of quercetin on pharmacokinetics of cefprozil in Chinese-Han male volunteers

Fei-Fei Jia, Zhi-Rong Tan, Howard L McLeod, Yao Chen, Dong-Sheng Ou-Yang, Hong-Hao Zhou
Xenobiotica; the fate of foreign compounds in biological systems 2016 46(10):896

Bibliography

PubMed
PMID 26928207
DOI
10.3109/00498254.2015.1132792
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignOpen-label two-period crossover interaction study
ModelHuman intervention research
Sample24 healthy Han Chinese men
InterventionQuercetin 500 mg/day for 15 days with a single cefprozil 500 mg dose
Duration15-day pretreatment and a 15-day washout
EndpointsSource-specific outcomes described in the key findings

What the study showed, in plain terms

Published in 2016, this source examined safety, interactions and special populations. Design: Open-label two-period crossover interaction study. Sample/model: 24 healthy Han Chinese men. The exposure or intervention was Quercetin 500 mg/day for 15 days with a single cefprozil 500 mg dose. Follow-up or treatment period: 15-day pretreatment and a 15-day washout.

Quercetin did not significantly alter cefprozil pharmacokinetics in this cohort.

Specific substrate, short exposure and narrow population. A null result for cefprozil does not exclude interactions with other medicines.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin Interactions: Medicines, Evidence and Precautions. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Quercetin did not significantly alter cefprozil pharmacokinetics in this cohort.
  • The recorded outcome domains were Source-specific outcomes described in the key findings.
  • The result applies to the tested exposure: Quercetin 500 mg/day for 15 days with a single cefprozil 500 mg dose; 15-day pretreatment and a 15-day washout.

What this study can and cannot tell us

  • Specific substrate, short exposure and narrow population. A null result for cefprozil does not exclude interactions with other medicines.
  • A change in blood exposure or a metabolic marker is not a demonstrated improvement in symptoms, disease events or lifespan. The tested formulation and co-administered medicines matter.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Phase 1 study of quercetin, a natural antioxidant for children and young adults with Fanconi anemia
Parinda A Mehta et al. · Blood advances · 2025
Tier 2
Randomised clinical trial to determine the safety of quercetin supplementation in patients with chronic obstructive pulmonary disease
Meilan K Han et al. · BMJ open respiratory research · 2020
Tier 2
Interaction study between antiplatelet agents, anticoagulants, diabetic therapy and a novel delivery form of quercetin
Antonella Riva et al. · Minerva cardioangiologica · 2019

Citation network

Articles citing this research paper

2 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology